Cipla rose 0.98% to Rs 463.10 after it acquired the brand name and trademark rights of the anti-diabetic drug, Vildagliptin for the Indian market.
Cipla said it has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years.
Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients primarily by enhancing pancreatic (α and β) islet functions. The drug is backed by strong clinical data & is therefore a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus. The current market size of Vildagliptin is Rs 818 crore as per IQVIA MAT November 2019 in India.
Cipla is a global pharmaceutical company focused on complex generics, and deepening of portfolio in markets of India, South Africa, North America, and key regulated and emerging markets. The company's strengths lay in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS) segments.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content